drugset / Trial / NCT00088491

Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

NCT00088491

Phase 3 Completed 1205 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine; evaluate different doses of IM olanzapine depot; and determine the blood levels of IM olanzapine depot in patients at different points in time after an injection.

Timeline

Start
2004-06
Primary completion
Completion
2006-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 10 mg Oral
Subject Olanzapine Small molecule 15 mg Oral
Subject Olanzapine Small molecule 20 mg Oral
Subject Olanzapine Small molecule 45 mg Intramuscular
Subject Olanzapine Small molecule 150 mg Intramuscular
Subject Olanzapine Small molecule 300 mg Intramuscular
Subject Olanzapine Small molecule 405 mg Intramuscular

Indications